Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer

BACKGROUND: The integration of residual cancer burden (RCB) and post‐treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long‐term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared wit...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Miglietta, Federica, Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Vernaci, Grazia, Menichetti, Alice, Faggioni, Giovanni, Giarratano, Tommaso, Mioranza, Eleonora, Genovesi, Elisa, Cumerlato, Enrico, Bottosso, Michele, Saibene, Tania, Michieletto, Silvia, Lo Mele, Marcello, Conte, Pierfranco, Guarneri, Valentina
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley & Sons, Inc. 2020
Θέματα:
Breast Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485331/
https://ncbi.nlm.nih.gov/pubmed/32618068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0201
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια